A Phase 2 interventional study of ViewRay MR-Linear Accelerator and Radiation therapy in Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer, sponsored by Washington University School of Medicine. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Treatment
How we know · 7 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Carcinoma, Non-Small-Cell Lung by Washington University School of Medicine — 2 open to participants now, 5 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Washington University School of Medicine.
Among the 30 studies in Carcinoma, Non-Small-Cell Lung by Washington University School of Medicine, this one is the 7th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2019, is one of 9 in phase 2, and was the 21st registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 30 studies in Carcinoma, Non-Small-Cell Lung by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 14
First in 2006; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 18 across the 26 interventional studies, 6 across the 4 observational. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
2 of the studies in Carcinoma, Non-Small-Cell Lung by Washington University School of Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04743505Washington University School of MedicineSafety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) | 2027-01-31 |
| NCT04791839Washington University School of MedicineSafety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer | 2027-04-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Carcinoma, Non-Small-Cell Lung by Washington University School of Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Building upon the clinical experience of the investigators with the magnetic resonance (MR)-guided radiation therapy system and applying principals of hypofractionation toward the current treatment paradigm of concurrent chemoradiation and consolidation immunotherapy for locally advanced non-small cell lung cancer (NSCLC), this prospective, single-arm Phase II clinical trial with safety lead-in will test the feasibility and outcomes of this approach.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical AJCC stage IIB or IIIA (AJCC, 8th ed.) with plans to be treated with concurrent chemoradiotherapy.
Appropriate stage for protocol entry based upon the following minimum diagnostic workup:
CBC/differential obtained within 30 days prior to registration, with adequate bone marrow function defined as follows:
Creatinine Clearance (male) = [(140 - age) x (wt in kg)] [(Serum Creatinine mg/dl) x (72)] Creatinine Clearance (female) = 0.85 x Creatinine Clearance (male)
Exclusion Criteria:
Severe, active comorbidity, defined as follows:
disease requiring active treatment, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis. Specific instances of autoimmune disease are eligible and allowed on study, as below:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* The first 6 patients enrolled on study will comprise the Safety Lead-In cohort and will be closely monitored for toxicity related specifically to the experimental chemoradiation portion of the study treatment. After these 6 patients have been enrolled, accrual will temporarily be suspended for a minimum of 6 months after completion of chemoradiation to allow for the evaluation of adverse events. * Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will be administered every 2 weeks or 4 weeks (timeline at the discretion of treating physician) for up to 12 months.
Device: ViewRay MR-Linear Accelerator · Radiation: Radiation therapy · Drug: Paclitaxel · Drug: Carboplatin AUC · Biological: Durvalumab
-Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will be administered every 2 weeks or 4 weeks (timeline at the discretion of the treating physician) for up to 12 months.
Device: ViewRay MR-Linear Accelerator · Radiation: Radiation therapy · Drug: Paclitaxel · Drug: Carboplatin AUC · Biological: Durvalumab
-Radiation will be delivered by this machine
-60Gy in 15 fractions
-50 mg/m\^2 intravenous
Also known as: Taxol
-2 mg/mL/min intravenous over 30 minutes
Also known as: Paraplatin
-10 mg/kg
Also known as: Imfinzi
Safety lead-in Only: Number of Participants With Dose Limiting Toxicities (DLTs)
* Safety of hypofractionated MRI-guided adaptive radiotherapy (60Gy/15 fractions) with concurrent chemotherapy (carboplatin and paclitaxel) and consolidation durvalumab is defined as \<2/6 participants experiencing dose limiting toxicities * DLT is defined as any possibly, probably, or definitely related to concurrent chemoradiation grade 3 toxicity that cannot be managed with maximal supportive care within 2 weeks, or any grade \> 4 toxicity that occurs during treatment * The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for all toxicity reporting.
Time frame: Through 6 months after completion of concurrent chemoradiation (estimated to be 6 months and 3 weeks)
Local Control Rate
-Defined as percentage of participants who do not have clinical and/or radiographic evidence of progression of disease at the primary (local) site
Time frame: Through completion of follow-up (median 731 days, full range: 72 days-1162 days)
Regional Control Rate
-Defined as the percentage of participants who do not have clinical and/or radiographic evidence of progression of disease at the previously involved or uninvolved hilar and/or mediastinal nodal (regional) sites
Time frame: Through completion of follow-up (median time 731 days, full range: 72 - 1162 days)
Number of Participants With Acute Toxicities by Worst Grade Experienced
-Graded per NCI CTCAE version 5.0
Time frame: From start of chemoradiation through 60 days
Number of Participants With Late Toxicities by Worst Grade Experienced
Graded per NCI CTCAE version 5.
Time frame: From 61 days after start of chemoradiation through 2 years after the start of chemoradiation
Tumor Response Rate
-Tumor response is defined as achieving a partial or complete response per RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Through completion of treatment (estimated to be 12 months and 3 weeks)
Distant Control Rate
-Defined as the number of participants who did not have distant recurrence. Distant recurrence is defined as the development of metastatic, non-local, and non-regional disease.
Time frame: Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
Incidence of Brain Metastases
-Defined as the percentage of participants who develop brain metastases.
Time frame: Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
Median Progression-free Survival (PFS) Probability
* PFS is defined as the months from start date of chemoradiation to either date of progression or death, whichever occurs first. Alive patients without progression are censored at the date of last follow-up or visit. * Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).
Time frame: Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
Median Disease-free Survival (DFS) Probability
DFS is defined as survival with no evidence of recurrent (local, regional or distant) disease or death
Time frame: Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
Median Overall Survival (OS) Probability
OS is defined as the months from the start date of chemoradiation to the date of death. Alive patients are censored at the date of last follow-up or visit.
Time frame: Through completion of follow-up (median 731 days, full range: 72 days - 1162 days)
| Milestone | Safety lead-in: Chemoradiation + Durvalumab | Phase II: Chemoradiation + Durvalumab |
|---|---|---|
| Started | 6 | 20 |
| Completed | 1 | 5 |
| Not completed | 5 | 15 |
| Withdrew: Adverse event | 3 | 7 |
| Withdrew: Disease progression | 2 | 6 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Death | 0 | 1 |
* Safety of hypofractionated MRI-guided adaptive radiotherapy (60Gy/15 fractions) with concurrent chemotherapy (carboplatin and paclitaxel) and consolidation durvalumab is defined as \<2/6 participants experiencing dose limiting toxicities * DLT is defined as any possibly, probably, or definitely related to concurrent chemoradiation grade 3 toxicity that cannot be managed with maximal supportive care within 2 weeks, or any grade \> 4 toxicity that occurs during treatment * The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for all toxicity reporting.
| Participants | Safety lead-in: Chemoradiation + Durvalumab |
|---|---|
| Safety lead-in Only: Number of Participants With Dose Limiting Toxicities (DLTs) | 0 |
-Defined as percentage of participants who do not have clinical and/or radiographic evidence of progression of disease at the primary (local) site
| Participants | Chemoradiation + Durvalumab |
|---|---|
| Local Control Rate | 22 |
-Defined as the percentage of participants who do not have clinical and/or radiographic evidence of progression of disease at the previously involved or uninvolved hilar and/or mediastinal nodal (regional) sites
| Participants | Chemoradiation + Durvalumab |
|---|---|
| Regional Control Rate | 24 |
-Graded per NCI CTCAE version 5.0
| Participants | Chemoradiation + Durvalumab Every 2 Weeks | Chemoradiation + Durvalumab Every 4 Weeks |
|---|---|---|
| Grade 1/2 Anemia | 2 | 0 |
| Grade 3/4/5 Supraventricular tachycardia | 1 | 0 |
| Grade 1/2 Constipation | 2 | 0 |
| Grade 1/2 Diarrhea | 1 | 0 |
| Grade 1/2 Dyspepsia | 2 | 1 |
| Grade 1/2 Dysphagia | 2 | 1 |
| Grade 1/2 Esophagitis | 8 | 2 |
| Grade 3/4/5 Esophagitis | 1 | 0 |
| Grade 1/2 Nausea | 3 | 1 |
| Grade 1/2 Vomiting | 0 | 1 |
| Grade 1/2 Fatigue | 3 | 1 |
| Grade 1/2 Chest Heaviness | 1 | 0 |
| Grade 1/2 Non-cardiac chest pain | 2 | 0 |
| Grade 1/2 Pain | 1 | 0 |
| Grade 3/4/5 Pain | 1 | 0 |
| Grade 3/4/5 Urinary tract infection | 1 | 0 |
| Grade 1/2 Bruising | 1 | 0 |
| Grade 1/2 Fall | 1 | 0 |
| Grade 1/2 Creatine increased | 1 | 0 |
| Grade 1/2 Lymphocyte count decreased | 3 | 1 |
| Grade 3/4/5 Lymphocyte count decreased | 11 | 2 |
| Grade 1/2 Neutrophil count decreased | 2 | 0 |
| Grade 3/4/5 Neutrophil count decreased | 1 | 0 |
| Grade 1/2 Platelet count decreased | 1 | 0 |
| Grade 1/2 White blood cell decreased | 3 | 0 |
| Grade 3/4/5 White blood cell decreased | 2 | 0 |
| Grade 1/2 Anorexia | 1 | 0 |
| Grade 1/2 Dehydration | 2 | 0 |
| Grade 1/2 Hyperglycemia | 1 | 0 |
| Grade 3/4/5 Hyperglycemia | 1 | 0 |
| Grade 1/2 Hyponatremia | 2 | 0 |
| Grade 3/4/5 Hyponatremia | 1 | 0 |
| Grade 1/2 Arthralgia | 2 | 0 |
| Grade 1/2 Back pain | 1 | 0 |
| Grade 1/2 Neck Pain | 1 | 0 |
| Grade 1/2 Pain in extremity | 1 | 0 |
| Grade 1/2 Headache | 2 | 0 |
| Grade 1/2 Anxiety | 1 | 0 |
| Grade 1/2 Insomnia | 2 | 0 |
| Grade 3/4/5 Aspiration | 1 | 0 |
| Grade 1/2 Cough | 1 | 0 |
| Grade 1/2 Dyspnea | 1 | 0 |
| Grade 1/2 Oropharyngeal pain | 1 | 0 |
| Grade 1/2 Pneumonitis | 1 | 0 |
| Grade 3/4/5 Respiratory failure | 1 | 0 |
| Grade 1/2 Rash maculo-papular | 1 | 0 |
| Grade 3/4/5 Hypertension | 1 | 0 |
| Grade 3/4/5 Thromboembolic event | 1 | 0 |
Graded per NCI CTCAE version 5.
| Participants | Chemoradiation + Durvalumab Every 2 Weeks | Chemoradiation + Durvalumab Every 4 Weeks |
|---|---|---|
| Grade 1/2 Anemia | 1 | 0 |
| Grade 3/4/5 Pericardial effusion | 1 | 0 |
| Grade 1/2 Sinus tachycardia | 1 | 0 |
| Grade 1/2 Hypothyroidism | 1 | 0 |
| Grade 1/2 Abdominal distension | 1 | 0 |
| Grade 1/2 Diarrhea | 1 | 0 |
| Grade 1/2 Dyspepsia | 1 | 0 |
| Grade 1/2 Dysphagia | 1 | 0 |
| Grade 3/4/5 Esophageal stenosis | 1 | 0 |
| Grade 3/4/5 Death NOS | 1 | 0 |
| Grade 3/4/5 Death due to disease progression | 5 | 1 |
| Grade 1/2 Fatigue | 2 | 1 |
| Grade 1/2 Fever | 1 | 0 |
| Grade 1/2 Non-cardiac chest pain | 2 | 0 |
| Grade 1/2 Pain | 1 | 0 |
| Grade 3/4/5 Pain | 1 | 0 |
| Grade 3/4/5 Cholecystitis | 1 | 0 |
| Grade 3/4/5 Hepatic failure | 1 | 0 |
| Grade 3/4/5 COVID-19 | 1 | 0 |
| Grade 1/2 Lung infection | 1 | 0 |
| Grade 3/4/5 Lung infection | 3 | 0 |
| Grade 3/4/5 Osteomyelitis | 1 | 0 |
| Grade 1/2 Skin infection | 1 | 0 |
| Grade 1/2 Upper respiratory infection | 1 | 0 |
| Grade 3/4/5 Dog Bite | 1 | 0 |
| Grade 3/4/5 Fall | 0 | 1 |
| Grade 1/2 Alanine aminotransferase increased | 1 | 0 |
| Grade 1/2 Creatine increased | 2 | 0 |
| Grade 3/4/5 Bicytopenia | 1 | 0 |
| Grade 1/2 Lymphocyte count decreased | 4 | 1 |
| Grade 3/4/5 Lymphocyte count decreased | 3 | 1 |
| Grade 1/2 Weight loss | 2 | 0 |
| Grade 1/2 White blood cell decreased | 1 | 0 |
| Grade 3/4/5 White blood cell decreased | 1 | 0 |
| Grade 3/4/5 Hypercalcemia | 1 | 0 |
| Grade 1/2 Hyperglycemia | 1 | 0 |
| Grade 1/2 Hyponatremia | 1 | 0 |
| Grade 3/4/5 Hyponatremia | 1 | 0 |
| Grade 1/2 Arthritis | 2 | 0 |
| Grade 1/2 Back pain | 2 | 0 |
| Grade 3/4/5 Back pain | 1 | 0 |
| Grade 1/2 Generalized muscle weakness | 0 | 1 |
| Grade 1/2 Muscle cramp | 1 | 0 |
| Grade 1/2 Muscle weakness upper limb | 1 | 0 |
| Grade 1/2 Ataxia | 1 | 0 |
| Grade 1/2 Headache | 1 | 0 |
| Grade 3/4/5 Seizure | 1 | 0 |
| Grade 1/2 Anxiety | 1 | 0 |
| Grade 1/2 Confusion | 1 | 1 |
| Grade 3/4/5 Confusion | 1 | 0 |
| Grade 1/2 Cough | 2 | 0 |
| Grade 1/2 Dyspnea | 4 | 1 |
| Grade 3/4/5 Dyspnea | 3 | 0 |
| Grade 1/2 Nasal congestion | 1 | 0 |
| Grade 1/2 Pleural effusion | 1 | 0 |
| Grade 3/4/5 Pleural effusion | 1 | 0 |
| Grade 1/2 Pneumonitis | 3 | 2 |
| Grade 3/4/5 Pneumonitis | 2 | 0 |
| Grade 3/4/5 Pneumothorax | 1 | 0 |
| Grade 3/4/5 Respiratory failure | 1 | 0 |
| Grade 3/4/5 Pulmonary nodular amyloidosis | 1 | 0 |
| Grade 3/4/5 Cough with hemoptysis | 1 | 0 |
| Grade 1/2 Sore throat | 1 | 0 |
| Grade 1/2 Wheezing | 1 | 0 |
| Grade 1/2 Hypertension | 1 | 0 |
| Grade 3/4/5 Hypertension | 0 | 1 |
| Grade 1/2 Lymphedema | 1 | 0 |
| Grade 3/4/5 Thromboembolic event | 3 | 0 |
-Tumor response is defined as achieving a partial or complete response per RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
| Participants | Chemoradiation + Durvalumab |
|---|---|
| Tumor Response Rate | 7 |
-Defined as the number of participants who did not have distant recurrence. Distant recurrence is defined as the development of metastatic, non-local, and non-regional disease.
| percentage of participants | Chemoradiation + Durvalumab |
|---|---|
| Distant Control Rate | 61.54 (42.53 to 77.57) |
-Defined as the percentage of participants who develop brain metastases.
| percentage of participants | Chemoradiation + Durvalumab |
|---|---|
| Incidence of Brain Metastases | 15.38 (6.15 to 33.53) |
* PFS is defined as the months from start date of chemoradiation to either date of progression or death, whichever occurs first. Alive patients without progression are censored at the date of last follow-up or visit. * Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).
| months | Chemoradiation + Durvalumab |
|---|---|
| Median Progression-free Survival (PFS) Probability | 8.84 (5.98 to NA) |
DFS is defined as survival with no evidence of recurrent (local, regional or distant) disease or death
| months | Chemoradiation + Durvalumab |
|---|---|
| Median Disease-free Survival (DFS) Probability | 8.84 (5.98 to NA) |
OS is defined as the months from the start date of chemoradiation to the date of death. Alive patients are censored at the date of last follow-up or visit.
| months | Chemoradiation + Durvalumab |
|---|---|
| Median Overall Survival (OS) Probability | 29.6 (19.94 to NA) |
Collected over Acute toxicities/adverse events are followed from start of treatment through 60 days. Late toxicities/adverse events are followed from 61 days from start of chemoRT up to 2 years. All-cause mortality was collected from start of treatment to death from any cause or completion of study follow-up (median time 731 days, full range 72-1162 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chemoradiation + Durvalumab Every 2 Weeks | 12/22 (54.5%) | 17/22 (77.3%) | 22/22 (100%) |
| Chemoradiation + Durvalumab Every 4 Weeks | 2/4 (50%) | 3/4 (75%) | 4/4 (100%) |
| Event | Chemoradiation + Durvalumab Every 2 Weeks | Chemoradiation + Durvalumab Every 4 Weeks |
|---|---|---|
| Death due to disease progressionGeneral disorders | 5/22 | 1/4 |
| FallInjury, poisoning and procedural complications | 0/22 | 1/4 |
| ConfusionPsychiatric disorders | 2/22 | 1/4 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 4/22 | 0/4 |
| Lung infectionInfections and infestations | 3/22 | 0/4 |
| Thromboembolic eventVascular disorders | 3/22 | 0/4 |
| Back painMusculoskeletal and connective tissue disorders | 2/22 | 0/4 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/22 | 0/4 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/22 | 0/4 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/22 | 0/4 |
| Event | Chemoradiation + Durvalumab Every 2 Weeks | Chemoradiation + Durvalumab Every 4 Weeks |
|---|---|---|
| Acute - Lymphocyte count decreasedInvestigations | 14/22 | 3/4 |
| Acute - EsophagitisGastrointestinal disorders | 9/22 | 2/4 |
| Late - Lymphocyte count decreasedInvestigations | 7/22 | 2/4 |
| Late - PneumonitisRespiratory, thoracic and mediastinal disorders | 3/22 | 2/4 |
| Acute - DyspepsiaGastrointestinal disorders | 2/22 | 1/4 |
| Acute - DysphagiaGastrointestinal disorders | 2/22 | 1/4 |
| Acute - NauseaGastrointestinal disorders | 3/22 | 1/4 |
| Acute - VomitingGastrointestinal disorders | 0/22 | 1/4 |
| Acute - FatigueGeneral disorders | 3/22 | 1/4 |
| Late - FatigueGeneral disorders | 1/22 | 1/4 |
| Age, Continuous(years) | Safety lead-in: Chemoradiation + Durvalumab | Phase II: Chemoradiation + Durvalumab | Total |
|---|---|---|---|
| Mean | 65.8 (61 to 73) | 67.1 (57 to 79) | 66.8 (57 to 79) |
| Sex: Female, Male(Participants) | Safety lead-in: Chemoradiation + Durvalumab | Phase II: Chemoradiation + Durvalumab | Total |
|---|---|---|---|
| Female | 3 | 9 | 12 |
| Male | 3 | 11 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Safety lead-in: Chemoradiation + Durvalumab | Phase II: Chemoradiation + Durvalumab | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 6 | 19 | 25 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Safety lead-in: Chemoradiation + Durvalumab | Phase II: Chemoradiation + Durvalumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 4 |
| White | 5 | 17 | 22 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Safety lead-in: Chemoradiation + Durvalumab | Phase II: Chemoradiation + Durvalumab | Total |
|---|---|---|---|
| United States | 6 | 20 | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2019 to primary completion in Sep 2025, 75 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's 75 months is above that.
Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →
Washington University School of Medicine →